<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Alice T. Shaw et al.|Clinical Cancer Research|2016Cited by 1.2k
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade TherapyChristina Pfirschke, Mikaël J. Pittet, Camilla Engblom et al.|Immunity|2016Cited by 954
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of <i>ALK</i> -Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryMari Mino–Kenudson, Scott J. Rodig|Clinical Cancer Research|2010Cited by 423
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Autoimmune Pancreatitis: A Systemic Immune Complex Mediated DiseaseVikram Deshpande, Gregory Y. Lauwers, Sonia L. Chicano et al.|The American Journal of Surgical Pathology|2006Cited by 318